SCHEDULE: Vanguard Group Reports 0% Stake in Lexeo Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Lexeo Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Lexeo Therapeutics Inc. common stock (CUSIP: 52886X107).
• The filing reports 0% beneficial ownership of Lexeo Therapeutics Inc. common stock by The Vanguard Group.
• This change is a result of an internal realignment within The Vanguard Group, which became effective on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects an internal reporting change by Vanguard and does not convey any positive or negative sentiment regarding Lexeo Therapeutics Inc.'s operational or financial performance.

Risks

• No specific risks to Lexeo Therapeutics Inc. are mentioned in this administrative filing. The change primarily affects how The Vanguard Group's aggregate holdings are reported, potentially requiring investors to consult multiple filings for a complete picture of Vanguard's overall exposure.

Future Outlook

The Vanguard Group's subsidiaries and business divisions will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538. These entities are expected to continue pursuing the same investment strategies as previously.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Ashley Grim, Head of Global Fund Administration, The Vanguard Group)

Industry Context

StockSavvy.ai notes that this filing reflects an internal administrative change within The Vanguard Group, a major investment adviser, rather than a strategic divestment from Lexeo Therapeutics Inc. Such realignments are common among large financial institutions to optimize reporting structures and comply with regulatory guidance, such as SEC Release No. 34-39538. This does not indicate a change in investment thesis regarding Lexeo Therapeutics Inc. by Vanguard's underlying funds.

Comparison to Industry Standards

• This filing is an administrative update regarding beneficial ownership reporting by a large investment adviser. It does not contain performance metrics or operational results for Lexeo Therapeutics Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders of Lexeo Therapeutics Inc.: Minimal direct impact, as the underlying holdings by Vanguard's funds likely remain, just reported differently. No change in control or investment thesis is implied.
• Clients of The Vanguard Group: May need to consult disaggregated filings from Vanguard's subsidiaries to get a complete picture of Vanguard's overall exposure to Lexeo Therapeutics Inc.

Next Steps

• The Vanguard Group's subsidiaries and business divisions will report their beneficial ownership separately going forward, requiring investors to consult these disaggregated filings for a complete view of Vanguard's holdings.

Key Dates

Recommendation

This filing is purely administrative, detailing a change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not provide any new information regarding Lexeo Therapeutics Inc.'s financial performance, strategic direction, or operational health. Therefore, it offers no basis for a change in investment recommendation for Lexeo Therapeutics Inc. An investor should hold their position and await more substantive company-specific news.

Keywords

Lexeo Therapeutics Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Internal Realignment